Literature DB >> 6379124

Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions.

I J Fidler, E S Kleinerman.   

Abstract

The possibility that tumoricidal human blood monocytes would recognize and destroy tumorigenic targets but leave bystander nontumorigenic cells unharmed was investigated. Highly purified preparations of peripheral blood monocytes isolated from normal human donors were activated in vitro by incubation with human lymphokines encapsulated in multilamellar liposomes. The cytotoxic properties of these monocytes against several tumorigenic and nontumorigenic allogeneic target cell populations were assessed by an in vitro radioisotope-release assay. Various combinations of three tumorigenic and three nontumorigenic target-cell populations, labeled with either [3H]thymidine or [14C]thymidine, were mixed and plated onto monolayers of blood monocytes. In all combinations used, activated monocytes specifically lysed only allogeneic neoplastic cells. At least in vitro, activated human blood monocytes can recognize and selectively destroy neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379124     DOI: 10.1200/JCO.1984.2.8.937

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Human monocytes selectively bind to cells expressing the tumorigenic phenotype.

Authors:  H Shimizu; D Wyatt; R D Knowles; C D Bucana; E J Stanbridge; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  The systemic activation of macrophages by liposomes containing immunomodulators.

Authors:  R Nayar; I J Fidler
Journal:  Springer Semin Immunopathol       Date:  1985

Review 4.  Therapy of disseminated melanoma by liposome-activated macrophages.

Authors:  I J Fidler
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon gamma in the peripheral blood monocytes of patients with solid tumors: modulation by arachidonic acid metabolic inhibitors.

Authors:  D P Braun; K P Siziopikou; L C Casey; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Activated monocytes kill malignant brain tumor cells in vitro.

Authors:  M Kirsch; H Fischer; G Schackert
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.

Authors:  M Maeda; T Asano; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

9.  GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.

Authors:  Serena S Kwek; James Kahn; Samantha K Greaney; Jera Lewis; Edward Cha; Li Zhang; Robert W Weber; Lonnie Leonard; Svetomir N Markovic; Lawrence Fong; Lynn E Spitler
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

10.  Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.

Authors:  S Sone; T Utsugi; P Tandon; H Yanagawa; A Okubo; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.